Concentrating power of the kidney after five years of pitressin-tannate therapy in a patient with diabetes insipidus untreated for 13 years. (Investigations during intravenous administration of hypertonic sodium chloride, lysine-vasopressin, clopamide and furosemide).
D003005:Clopamide / Q000008:administration & dosage; D003919:Diabetes Insipidus / Q000188:drug therapy*; D004231:Diuresis / Q000187:drug effects; D005260:Female; D005665:Furosemide / Q000008:administration & dosage; D006801:Humans; D006982:Hypertonic Solutions / Q000008:administration & dosage; D007671:Kidney Concentrating Ability / Q000187:drug effects*; D008239:Lysine / Q000008:administration & dosage; D008875:Middle Aged; D012965:Sodium Chloride / Q000008:administration & dosage; D014667:Vasopressins / Q000008:administration & dosage / Q000627:therapeutic use*
D006982:Hypertonic Solutions; D014667:Vasopressins; D003005:Clopamide; D012965:Sodium Chloride; D005665:Furosemide; D008239:Lysine